Successful Treatment of KIT D816V-positive, Imatinib-resistant Systemic Mastocytosis with Interferon-alpha

被引：12

作者：

Yoshida, Chikamasa ^{[1
]}

Takeuchi, Makoto ^{[1
]}

Tsuchiyama, Junjiro ^{[2
]}

Sadahira, Yoshito ^{[2
]}

机构：

[1] Natl Hosp Org Minami Okayama Med Ctr, Dept Internal Med, Div Hematol, Okayama, Japan

[2] Kawasaki Med Sch, Dept Pathol, Kurashiki, Okayama, Japan

来源：

INTERNAL MEDICINE | 2009年 / 48卷 / 22期

关键词：

mastocytosis; myeloproliferative neoplasm; KIT; imatinib; interferon-alpha; CLINICAL PHARMACOKINETICS; MAST-CELLS; DISORDERS; LEUKEMIA; OPTIONS;

D O I：

10.2169/internalmedicine.48.2294

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe a case of systemic mastocytosis associated with myelodysplastic syndrome. The bone marrow showed multifocal clusters of mast cells and myeloid dysplasia. Sequencing of the KIT DNA revealed a point mutation at codon 816 including a substitution of valine for aspartic acid (D816V). The patient's tumor did not respond to imatinib; however, interferon-alpha reduced the bone marrow mast cells and serum total tryptase. The patient remains alive at one year after the diagnosis without disease progression.

引用

页码：1973 / 1978

页数：6

共 20 条

[1] Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit [J].

Akin, C ;

Brockow, K ;

D'Ambrosio, C ;

Kirshenbaum, AS ;

Ma, YS ;

Longley, BJ ;

Metcalfe, DD .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) :686-692

[2] Practical management of patients with chronic myeloid leukemia receiving imatinib [J].

Deininger, MWN ;

O'Brien, SG ;

Ford, JM ;

Druker, BJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1637-1647

[3] Clinical pharmacokinetics of quetiapine - An atypical antipsychotic [J].

DeVane, CL ;

Nemeroff, CB .

CLINICAL PHARMACOKINETICS, 2001, 40 (07) :509-522

[4] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor [J].

Heinrich, MC ;

Griffith, DJ ;

Druker, BJ ;

Wait, CL ;

Ott, KA ;

Zigler, AJ .

BLOOD, 2000, 96 (03) :925-932

[5]

Horny H-P., 2008, WHO classification of Tumours of Haematopoietic and Lymphoid Tissues, V4th, P54

[6] Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge [J].

Horny, HP ;

Sotlar, K ;

Sperr, WR ;

Valent, P .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (06) :604-608

[7] Mast cells and mastocytosis [J].

Metcalfe, Dean D. .

BLOOD, 2008, 112 (04) :946-956

[8] FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia [J].

Pardanani, A ;

Brockman, SR ;

Paternoster, SF ;

Flynn, HC ;

Ketterling, RP ;

Lasho, TL ;

Ho, CL ;

Li, CY ;

Dewald, GW ;

Tefferi, A .

BLOOD, 2004, 104 (10) :3038-3045

[9] Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia [J].

Pardanani, A ;

Reeder, T ;

Li, CY ;

Tefferi, A .

LEUKEMIA RESEARCH, 2003, 27 (10) :883-885

[10] Clinical pharmacokinetics of imatinib [J].

Peng, B ;

Lloyd, P ;

Schran, H .

CLINICAL PHARMACOKINETICS, 2005, 44 (09) :879-894

← 1 2 →